Download PDF
Klin Padiatr 2008; 220(2): 93-100
DOI: 10.1055/s-2007-985864
Übersichtsartikel

© Georg Thieme Verlag KG Stuttgart · New York

Methylphenidat-Retard-Präparate bei Kindern und Jugendlichen mit ADHs - eine Übersicht

Methylphenidate of Retard Forms in Children and Adolescents with ADHD - an OverviewR. Pelz 1 , T. Banaschewski 1 , K. Becker 1
  • Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit, Mannheim
Further Information

Publication History

Publication Date:
21 December 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Zum jetzigen Zeitpunkt sind Stimulanzien das Mittel der Wahl zur pharmakologischen Behandlung einer Aufmerksamkeits-/Hyperaktivitätsstörung (ADHS). Sie sind indiziert, wenn verhaltenstherapeutische und psychoedukative Maßnahmen alleine nicht ausreichen. Die Wirkdauer von schnell freisetzenden Präparaten ist oft nicht ausreichend. Mittlerweile wurden verschiedene retardierte Methylphenidatpräparate entwickelt und auch für den deutschen Markt zugelassen. Der Artikel gibt eine Übersicht über die klinischen Studien zu Wirksamkeit, Wirkdauer und Nebenwirkungsprofil der in Deutschland erhältlichen Darreichungsformen von Stimulanzien. In der klinischen Anwendung sind die neuen Retard-Produkte wirkungsvolle Alternativen, da die kontinuierliche mehrstufige Freisetzung des Wirkstoffs über den Tag verteilt nach morgendlicher Einmalgabe Vorteile bietet. Allerdings müssen unerwünschte Arzneimittelwirkungen durch die verlängerte Wirkungsdauer genau beobachtet werden. Eine individuelle Anpassung an die jeweiligen Erfordernisse der verschiedenen tageszeitabhängigen Bedürfnisse der Kinder und Jugendlichen ist erforderlich. Möglicherweise kann eine Kombination mit unretardiertem MPH zu einer besseren Wirkungs-/Nebenwirkungsrelation führen.

Abstract

As yet, stimulants remain the preferred means of treating attention-deficit/hyperactivity disorder (ADHD) pharmacologically. They are indicated when measures based on behavioural therapy or psychoeducation alone are not sufficient. How-ever, the period of effectiveness of immediate release stimulants is often not satisfactory. A variety of retarded forms of methylphenidate have now been developed and approved for the German market. This paper presents an overview of clinical studies on effectiveness, period of effectiveness and the profile of side effects of different forms stimulants available in Germany. In clinical practice, the new retard products represent effective alternatives. There is an advantage in administering this drug in a once-daily single dose. At the same time, the side effects that are caused by an extended period of effectiveness have to be studied in detail. A more precise adaptation to the daily obligations and needs of children and adolescents is needed. Possibly, a combination with unretareded MPH might lead to a better effect/side-effect profile.

Schlüsselwörter

ADHS - Pharmakotherapie - Methylphenidat - Retardformen - Psychostimulanzien - Nebenwirkungen

Key words

ADHD - pharmacotherapy - methylphenidate - retarded forms of methylphenidate side effects

Literatur

  • 1 American Academy of Pediatrics . Clinical Practice Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity Disorder.  Pediatrics. 2000;  105 1158-1170
    CrossrefPubMedGoogle Scholar
  • 2 American Psychiatric Association .Diagnostic and Statistical Manual for Mental Disorders. 4th ed. Washington, DC 1994
  • 3 Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E. Long-acting medications for the hyperkinetic disorders: A systematic review and European treatment guideline.  Eur Child Adolesc Psychiatry. 2006;  15 476-495
    CrossrefPubMedGoogle Scholar
  • 4 Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: Antisocial activities and drug use.  Journal of Child Psychology and Psychiatry. 2004;  45 195-211
    CrossrefPubMedGoogle Scholar
  • 5 Baumgaertel A, Wolraich M, Dietrich M. Comparison of diagnostic criteria for attention deficit disorder in a German elementary school sample.  J. Am. Acad. Child Adolesc Psychiatry. 1995;  34 629-638
    PubMedGoogle Scholar
  • 6 Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie. et al. (Hrsg). Döpfner M, Lehmkuhl G. Hyperkinetische Störungen (F90). Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter, 3.überarbeitete und erweiterte Auflage. Deutscher Ärzte-Verlag 2007
    Google Scholar
  • 7 Döpfner M, Lehmkuhl G. Evidenzbasierte Therapie von Kindern und Jugendlichen mit ADHS.  Prax Kinderpsychol Kinderpsychiatr. 2002;  51 419-440
    PubMedGoogle Scholar
  • 8 Döpfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von Muller G, Gunter M, Hassler F, Ose C, Rothenberger A, Schmeck K, Sinzig J, Stadler C, Uebel H, Lehmkuhl G. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting.  Eur Child Adolesc Psychiatry. 2004;  13 ((Suppl 1)) I93-101
    PubMedGoogle Scholar
  • 9 Dillon A. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. National Institute of Clinical Excellence, London 2006
  • 10 Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders?.  Journal of Clinical Psychiatry. 2003;  64 ((suppl 11)) 9-13
    PubMedGoogle Scholar
  • 11 Gonzalez MA, Pentikis HS, Anderl N, Benedict MF, Cory HH De, Dirksen SJ, Hatch SJ. Methylphenidate bioavailability from two extended-release formulations.  Int J Clin Pharmacol Ther. 2002;  40 175-184
    PubMedGoogle Scholar
  • 12 Holtkamp K, Peters-Wallraf B, Wüller S, Pfäffle R, Herpertz-Dahlmann B. Case Report: Methylphenidate-related growth impairment.  J Child Adolesc Psychopharm. 2002;  12 55-61
    PubMedGoogle Scholar
  • 13 Jadad AR, Booker L, Gould M, Kakuma R, Boyle M, Cunningham CE, Kim M, Schachar R. The treatment of attention-deficit hyperactivity disorder: An annotated bibliography and critical appraisal of published systematic reviews and metaanalyses.  Can J Psychiatr. 1999;  44 1025-1035
    PubMedGoogle Scholar
  • 14 Janssen-Cilag GmbH.. , Fachinformation Concerta® 18 mg/36 mg/54 mg Retardtabletten. 41457 Neuss. http://www.janssen-cilag.de
    PubMed
  • 15 Jerome L. Can methylphenidate facilitate sleep in children with attention deficit hyperactivity disorder?.  J Child Adolesc Psychopharm. 2001;  11 109
    PubMedGoogle Scholar
  • 16 Kent JD, Blader JC, Koplewicz HS, Abikoff H, Foley CA. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder.  Pediatrics. 1995;  96 320-325
    PubMedGoogle Scholar
  • 17 Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate.  Clin Pharmacokinet. 1999;  37 457-470
    CrossrefPubMedGoogle Scholar
  • 18 King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R. , Methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children (commercial in confidence information removed) 2004; Centre for Reviews and Dissemination (CRD): http://www.nice.org.uk/pdf/ADHD_assessment_report.pdf
    PubMed
  • 19 Lisska MC, Rivkees SA. Daily methylphenidate use slows growth of children: a community based study.  J Pediatr Endocrinol Metab. 2003;  16 711-718
    CrossrefPubMedGoogle Scholar
  • 20 Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.  Paediatr Drugs. 2003;  5 545-555
    PubMedGoogle Scholar
  • 21 Mannuzza S, Klein R, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys grown up.  Arch Gen Psychiatry. 1998;  155 493-498
    Google Scholar
  • 22 Marchetti A, Magar R, Lau H, Murphy EL, Jensen PS, Conners CK, Findling R, Wineburg E, Carotenuto I, Einarson TR, Iskedjian M. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.  Clin Ther. 2001;  23 1904-1921 , 39
    CrossrefPubMedGoogle Scholar
  • 23 Markowitz JS, Straughn AB, Patrick KS, Vane CL De, Pestreich L, Lee J, Wang Y, Muniz R. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.  Clin Pharmacokinet. 2003;  42 393-401
    CrossrefPubMedGoogle Scholar
  • 24 MEDICE Arzneimittel Pütter GmbH & Co.KG .FACHINFORMATION Medikinet retard 10 mg/20 mg/30 mg/40 mg. Kuhloweg 37, 58638 Iserlohn http://www.medice.de
  • 25 MTA Cooperative Group . A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactivity disorder.  Archives of General Psychiatry. 1999a;  56 1073-1086
    CrossrefPubMedGoogle Scholar
  • 26 MTA Cooperative Group . Moderators and mediators of treatment response for children with attentiondeficit/hyperactivity disorder.  Archives of General Psychiatry. 1999b;  56 1088-1096
    CrossrefPubMedGoogle Scholar
  • 27 Novartis Pharmaceuticals Corp .Ritalin LA (methylphenidate HCL) product monograph. East Hanover (NJ): Novartis Pharmaceuticals Corp 2002
  • 28 Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD. Once a day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.  Pediatrics. 2001;  107 E105
    CrossrefPubMedGoogle Scholar
  • 29 Pelham WE, Karen E, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and Pemoline.  Pediatrics. 1990;  86 226-236
    PubMedGoogle Scholar
  • 30 Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK, MacCracken JT, Swanson JM, Hughes CW, Llana ME, Lopez M, Toprac MG. The texas children's medication algorithm project: report of the texas consensus conference panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Attention-deficit/hyperactivity disorder.  J. Am. Acad. Child Adolesc Psychiatry. 2000;  39 908-927
    PubMedGoogle Scholar
  • 31 Remschmidt H, Schmidt M, Poustka F. Multiaxial classification of child and adolescent psychiatric disorders. [In German: Multiaxiales Klassifikationsschema für psychische Störungen des Kindes- und Jugendalters nach ICD-10 und DSM.IV.] 4. überarbeitete und erweiterte Auflage, Bern 2001
    Google Scholar
  • 32 Rupprecht T, Schellmoser S, Wagner M, Wenzel D, Topf HG. Aufmerksamkeitsdefizit-Hyperaktivitäts-Syndrom (ADHS).  Monatsschr Kinderheilkd. 2005;  153 463-468
    CrossrefPubMedGoogle Scholar
  • 33 Sevecke K, Dittmann R, Lehmkuhl G, Döpfner M. Atomoxetinbehandlung von Kindern und Jugendlichen mit ADHS.  Monatsschr Kinderheilkd. 2006;  154 894-902
    CrossrefPubMedGoogle Scholar
  • 34 Sinzig JK, Gontard A von. Absences as differential diagnosis in children with attention-deficit disorder.  Klin Padiatr.. 2005;  217 230-233
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 SIGN (Scottish Intercoligiate Guidelines Networt) .Attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline. Vol. 52 Edinburgh 2001
  • 36 SIGN (Scottish Intercoligiate Guidelines Networt) .A guidelines developer's handbook. SIGN, Edinburgh 2004
  • 37 Sonuga-Barke EJ, Swanson JM, Coghill D, Cory HH De, Hatch SJ. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.  BMC Psychiatry. 2004;  4 28
    CrossrefPubMedGoogle Scholar
  • 38 Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S. Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the life cycle.  J. Am. Acad. Child Adolesc Psychiatry. 1996;  35 409-432
    PubMedGoogle Scholar
  • 39 Swanson J, Greenhill L, Pelham W, Wilens T, Wolraich M, Abikoff H, Atkins M, August G, Biederman J, Bukstein O, Conners CK, Efron L, Fiebelkorn K, Fried J, Hoffman M, Lambrecht L, Lerner M, Leventhal B, MacBurnett K, Morse E, Palumbo D, Pfiffner L, Stein M, Wigal SB, Winans E. Initiating Concerta TM (Oros_methylphenidate HCl) in children with attention-deficit hyperactivity disorder.  J Clin Res. 2000;  3 59-76
    PubMedGoogle Scholar
  • 40 Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).  Pediatrics. 2004;  113 e206-e216
    CrossrefPubMedGoogle Scholar
  • 41 Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A. European clinical guidelines for hyperkinetic disorder - first upgrade.  Eur Child Adolesc Psychiatry. 2004;  13 ((Suppl 1)) 17-30
    CrossrefPubMedGoogle Scholar
  • 42 Taylor E, Sergeant J, Doepfner M, Gunning B, Overmeyer S, Möbius H-J, Eisert H-G. Clinical guidelines for hyperkinetic disorder.  Eur Child Adolesc Psychiatry. 1998;  7 184-200
    CrossrefPubMedGoogle Scholar
  • 43 UCB GmbH . 2006;  , Fachinformation. Equasym® Retard. Hüttenstraße 205, 50170 Kerpen.
  • 44 Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse?.  A meta-analytic review of the literature. Pediatrics. 2003;  111 179-185
    CrossrefPubMedGoogle Scholar
  • 45 Wilens T, Pelham W, Stein M, Conners KC, Abikoff H, Atkins M, August G, Greenhill L, MacBurnett K, Palumbo D, Swanson J, Wolraich M. ADHD treatment with once-daily OROS® methylphenidate: interim 12-month results from a long-term open-label study.  J. Am. Acad. Child Adolesc Psychiatry. 2003;  42 424-433
    CrossrefPubMedGoogle Scholar
  • 46 Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, MacBurnett K, Bukstein O, August G. Randomized, controlled trial of oros methylphenidate once a day in children with attentiondeficit/hyperactivity disorder.  Pediatrics. 2001;  108 883-892
    CrossrefPubMedGoogle Scholar

Korrespondenzadresse

Dr. R. Pelz

Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit

Postfach 12 21 20

68072 Mannheim

Phone: +49/621/1703 45 41

Fax: +49/621/1703 45 05

Email: reta.pelz@zi-mannheim.de

      >